Sanofi (NYSE:SNY) traded down 0.3% during mid-day trading on Friday . The company traded as low as $40.82 and last traded at $40.85, with a volume of 617,239 shares traded. The stock had previously closed at $40.99.

A number of equities research analysts have issued reports on the company. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Wednesday, May 4th. HSBC cut Sanofi from a “buy” rating to a “hold” rating in a research report on Tuesday, May 3rd. Bank of America Corp. reaffirmed a “buy” rating and set a $58.00 target price on shares of Sanofi in a research report on Tuesday, May 3rd. Barclays PLC raised Sanofi from an “equal weight” rating to an “overweight” rating in a research report on Thursday, May 12th. Finally, JPMorgan Chase & Co. reissued a “sell” rating on shares of Sanofi in a research report on Monday, April 25th. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $49.67.

The stock has a market capitalization of $105.27 billion and a PE ratio of 22.31. The company has a 50-day moving average of $40.34 and a 200 day moving average of $40.76.

A number of large investors have recently made changes to their positions in SNY. Stephens Inc. AR raised its stake in shares of Sanofi by 4.5% in the fourth quarter. Stephens Inc. AR now owns 56,811 shares of the company’s stock worth $2,423,000 after buying an additional 2,424 shares in the last quarter. Freestone Capital Holdings LLC purchased a new stake in shares of Sanofi during the fourth quarter worth about $1,672,000. Cypress Asset Management Inc. TX raised its stake in shares of Sanofi by 39.2% in the fourth quarter. Cypress Asset Management Inc. TX now owns 75,680 shares of the company’s stock worth $3,228,000 after buying an additional 21,300 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Sanofi by 0.7% in the fourth quarter. Bank of Montreal Can now owns 389,519 shares of the company’s stock worth $16,614,000 after buying an additional 2,560 shares in the last quarter. Finally, Haverford Trust Co. raised its stake in shares of Sanofi by 3.5% in the fourth quarter. Haverford Trust Co. now owns 500,192 shares of the company’s stock worth $21,333,000 after buying an additional 16,855 shares in the last quarter.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.